Monocyte Chemoattractant Protein-1 2518A/G Polymorphism

NCT ID: NCT02077127

Last Updated: 2014-03-05

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 1043 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2011-09-30
• Study Completion Date: 2013-04-30

Brief Summary

The pathogenesis of proliferative diabetic retinopathy (PDR) remains poorly understood. Recent studies have implicated that monocyte chemoattractant protein-1 (MCP-1) is associated with diabetic microvascular or macrovascular complications. However, the relationship between SNP polymorphism c.2518A/G in the MCP-1 gene with diabetic retinopathy remains controversial. In the present study, we evaluated the association of a single nucleotide polymorphism (SNP) in the MCP-1 gene with diabetic retinopathy (DR) and diabetic macular edema (DME) in Chinese population from Southern China with type 2 diabetes.

Detailed Description

The association between polymorphism of MCP-1 c.2518A/G and DR had been reported in Japan and Korea, but their opinion were inconsistent. However there is no report in China so far. This study was designed to clarify the relationship of polymorphism of MCP-1 c.2518A/G with type 2 diabetes with or without DR. The relationship between MCP-1 c.2518A/G and different stage of DR has also been studied.This article proved that the MCP-1 c.2518G/G genotype is a susceptibility gene for DR in Chinese type 2 diabetic patients, especially the High-risk PDR. There is no association with DME and c.2518G/G.

Conditions

Diabetic Retinopathy

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: CROSS_SECTIONAL

Eligibility Criteria

Inclusion Criteria

• Type 2 diabetic retinopathy
• age at diagnosis ≥30 years and a known duration of diabetes of ≥5 years.

Exclusion Criteria

• eyeball atrophy
• epimacular membrane
• age-related macular degeneration (ARMD)
• intravitreal injection medicine
• vitreous hemorrhage

• Minimum Eligible Age: 41 Years
• Maximum Eligible Age: 68 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Harbin Medical University

OTHER

Sponsor Role: lead

Responsible Party

Li Dong

Li Dong

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Ping Liu, Doctor

Role: STUDY_CHAIR

First Affiliated Hospital of Harbin Medical University

Locations

Harbin Medical University

Harbin, Heilongjiang, China

Countries

China

Other Identifiers

dongli

Identifier Type: -

Identifier Source: org_study_id